Pentoxifylline is an orally active drug used to treat peripheral vascular disease, cerebrovascular disease, and other conditions involving impaired microcirculation. It primarily works by increasing red blood cell deformability, reducing blood viscosity, and decreasing platelet aggregation and thrombus formation. Extensive studies show that pentoxifylline, at doses of 600 to 1200 mg/day for at least 6 weeks, improves symptoms in 60 to 100% of patients with peripheral vascular disease, including walking distance, rest pain, muscle blood flow, and leg ulcers. It is more effective than placebo and other drugs like nylidrin, adenosine, and naftidrofuryl. In cerebrovascular disease, pentoxifylline improves clinical outcomes in about 85% of patients, with benefits in cerebral blood flow, especially in ischemic areas. It is effective in transient ischemic attacks, sequelae of cerebral thrombosis and hemorrhage, and chronic ischemic disorders. In chronic cerebrovascular disease, pentoxifylline shows significant clinical benefit compared to placebo and is superior to drugs like co-dergocrine mesylate, adenosine, and pyrithioxine. Preliminary studies suggest pentoxifylline may also be useful in sickle cell disease, some hearing disorders, eye circulation disorders, high altitude sickness, and asthenozoospermia. It is generally well-tolerated when administered as a controlled-release formulation, with gastrointestinal symptoms being the most common side effect. The drug is well-absorbed, distributed throughout the body, metabolized in the liver, and excreted mainly through the kidneys. Its elimination half-life is around 3-4 hours. It is recommended for use in various conditions involving impaired microcirculation.Pentoxifylline is an orally active drug used to treat peripheral vascular disease, cerebrovascular disease, and other conditions involving impaired microcirculation. It primarily works by increasing red blood cell deformability, reducing blood viscosity, and decreasing platelet aggregation and thrombus formation. Extensive studies show that pentoxifylline, at doses of 600 to 1200 mg/day for at least 6 weeks, improves symptoms in 60 to 100% of patients with peripheral vascular disease, including walking distance, rest pain, muscle blood flow, and leg ulcers. It is more effective than placebo and other drugs like nylidrin, adenosine, and naftidrofuryl. In cerebrovascular disease, pentoxifylline improves clinical outcomes in about 85% of patients, with benefits in cerebral blood flow, especially in ischemic areas. It is effective in transient ischemic attacks, sequelae of cerebral thrombosis and hemorrhage, and chronic ischemic disorders. In chronic cerebrovascular disease, pentoxifylline shows significant clinical benefit compared to placebo and is superior to drugs like co-dergocrine mesylate, adenosine, and pyrithioxine. Preliminary studies suggest pentoxifylline may also be useful in sickle cell disease, some hearing disorders, eye circulation disorders, high altitude sickness, and asthenozoospermia. It is generally well-tolerated when administered as a controlled-release formulation, with gastrointestinal symptoms being the most common side effect. The drug is well-absorbed, distributed throughout the body, metabolized in the liver, and excreted mainly through the kidneys. Its elimination half-life is around 3-4 hours. It is recommended for use in various conditions involving impaired microcirculation.